Search

everythinglearnresearchcommunity

for

Search:↓

Researching the cause of hair loss and treating it by preventing DHT in the scalp with medication such as finasteride or dutasteride, estrogen, minoxidil, dermarolling, and possible topical antiandrogens.

A user started using RU58841 for hair loss and experienced anxiety and physical discomfort. Other users suggested avoiding the treatment due to similar side effects and recommended alternative treatments like pyri.

The user switched from finasteride to dutasteride due to side effects and is experiencing fewer side effects with dutasteride, though some scalp itching has occurred. Blood tests show elevated testosterone and estrogen, low DHT, and normal liver and cholesterol levels, leading the user to feel confident in the long-term benefits of dutasteride for hair regrowth.

Pyrilutamide and RU58841 are androgen receptor antagonists that block receptors without significantly reducing testosterone or DHT levels. Any indirect effect on androgen levels is likely negligible.

Pyrilutimide and CB-03-01, two treatments for hair loss, have similar clinical trial results despite different binding affinities to androgen receptors. Factors other than binding affinity, like the time a drug stays bound to the receptor, may influence their effectiveness.

Chinese researchers have successfully created hair follicles in vitro, potentially offering unlimited hair for transplantation and a cure for hair loss. They plan to test these follicles in vivo on human scalps.

The conclusion of the conversation is that some individuals may experience a condition called reactionary hypergonadism when taking dutasteride for hair loss. This condition can lead to an increase in testosterone levels, which may worsen hair loss instead of improving it.

New product Tomorrowlabs HSF targets hair loss through HIF pathway indirectly by removing scalp iron. Minoxidil and Stemoxydine also relate to HIF pathway.

A case study that suggests verteporfin may be able to help regrow donor hairs after FUE extraction, and the potential implications of this result. Treatments discussed include Minoxidil, Finasteride, and RU58841.

The user is using RU58841 for hair regrowth on the temples and is considering adding minoxidil. They are questioning the potential for vellus hairs to develop into fuller hair and the possibility of reactivating dormant follicles.

User tried oral finasteride, topical finasteride, topical dutasteride, and RU58841 but experienced side effects. They discuss upcoming treatments like clascoterone, pyrilutamide, gt20029, and KY19382 as potential options.

A 22-year-old male experiencing hair loss suspects androgenetic alopecia (AGA) and possibly telogen effluvium (TE), with a noted improvement in scalp itch after adopting a gluten-free diet. He is advised to consider treatments like finasteride or minoxidil and to check iron and ferritin levels.

RU58841 remains active for several hours after application, and it's suggested to wait a few hours before washing it off to maintain its effectiveness. There is a concern about potential transfer to others if they touch the hair shortly after application.

The review discusses traditional hair loss treatments like minoxidil and finasteride, and newer options like Low-Level Laser Therapy, microneedling, and platelet-rich plasma for androgenetic alopecia. It highlights the need for more high-quality trials to assess these treatments' effectiveness and standardized protocols for emerging therapies.

The conversation discusses using Rogaine (Minoxidil) and ketoconazole for hair regrowth, with interest in trying a formulation with Azelaic Acid for potentially better results. Concerns about Azelaic Acid's effectiveness and safety, including skin sensitivity to sunburn, are mentioned.

The user experienced rapid diffuse hair thinning for five years despite no signs of AGA or miniaturization. They tried finasteride and oral minoxidil without success and have checked thyroid, iron, and vitamin D levels.

The conversation discusses potential future hair loss treatments, including SCUBE3, hair follicle cloning, and GT20029, with mentions of past disappointments like CosmeRNA and hopes for treatments like Verteporfin for infinite donor hair.

The user has been treating hair loss for over 11 years with various methods including Minoxidil, Keto shampoos, vitamins, and microneedling, but has avoided Finasteride due to fertility concerns. They have recently added Zix and The Ordinary Serum to their routine and are questioning their high DHT levels despite their efforts.

Some people may not respond to topical minoxidil due to low SULT1A1 enzyme activity, but oral minoxidil can be effective. Tretinoin may enhance minoxidil's effectiveness, and some users prefer oral minoxidil despite side effects.

A 28-year-old woman with genetic hair loss has tried various treatments, including oral minoxidil, finasteride, dutasteride, vitamins, ketoconazole shampoo, exosome needling, and hair extensions. She plans to pause treatments for pregnancy and is concerned about potential hair loss during that time.

The conversation discusses hair loss treatments, with the original poster using microneedling, rosemary oil, pumpkin seed oil, and Nizoral shampoo, and experiencing increased shedding. Responses suggest that shedding is typically a good sign only with medical treatments like minoxidil or finasteride, and recommend considering DHT blockers or medical treatments for effective results.

The conversation is about whether stemoxydine can shorten the dormant phase after a hair transplant, known as the ugly duckling phase. There is skepticism about whether it actually works as claimed.

Follicopeptide (FOL005) by Coegin Pharma will launch as a cosmetic hair growth treatment by Q2 2025, showing similar efficacy to finasteride. Users discuss the benefits and skepticism of releasing hair loss treatments as cosmetics rather than drugs.

A 41-year-old doctor shared his positive experience with a 4,100 graft hair transplant, highlighting the importance of a skilled doctor for a natural hairline. He mentioned a confidence boost and the occasional use of finasteride post-transplant.

PP405 shows promise in treating severe hair loss, with 31% of users experiencing over 20% hair density increase in four weeks, faster than minoxidil and finasteride. Some users are skeptical about the results' significance and long-term efficacy.

A user created a tracker for hair loss treatments in clinical development, including compounds like Dermaliq, RU58841, and Pyrilutamide. The tracker updates with new information and allows filtering by conditions like androgenetic alopecia (AGA) and alopecia areata (AA).

A user shared progress pictures showing significant hair regrowth after using 1mg finasteride and weekly microneedling for about 2.5 to 3 months. The user reported no side effects and maintained good health and mood.

Microneedling's effectiveness for hair growth is debated, with some suggesting it enhances minoxidil absorption, but evidence is inconclusive. Concerns exist about its impact on hair transplants, and opinions vary on its use with other treatments like RU58841 and stemoxydine.

HMI-115 is a new drug developed by Bioinvent and licensed by Bayer, with mixed opinions on its potential effectiveness. Some users are skeptical and prefer proven treatments like Minoxidil, finasteride, and RU58841.

The conversation discusses RU58841, a compound for hair loss treatment, which was found to be effective in a 6-month trial but was not pursued due to financial issues or marketability concerns, not safety. Some users are considering crowdfunding to release the research data, while others discuss personal experiences and safety concerns with RU58841.